Brief: Lidds: Sting Study Opens Up Multi-Billion Dollar Cancer Immunotherapy Market
30/07/2018 09:22
July 30 (Reuters) - Lidds AB LIDDS.ST :
* REG-NEW STING STUDY OPENS UP MULTI-BILLION DOLLAR CANCER IMMUNOTHERAPY MARKET FOR LIDDS
UNIQUE
NANOZOLID® TECHNOLOGY
* PRECLINICAL STUDY: INJECTION OF NANOZOLID FORMULATED STING-AGONIST HAS EQUAL OR BETTER
EFFICACY
VERSUS STANDARD STING-AGONIST TREATMENT
Source text for Eikon: ID:nGNE5RV7qq
Further company coverage: LIDDS.ST
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Lidds AB
See all newsBrief: Liquidator To Apply For Lidds To Be Declared Bankrupt
Brief: Lidds To Delist Shares From Nasdaq First North
Brief: Lidds Proposes Voluntary Liquidation And Delisting
Brief: Lidds Decides To Terminate Process Regarding Reverse Acquisition Of Proport Invest
Brief: Lidds Signs Agreement For Reverse Takeover Of Proport Invest